Non-invasive glucose monitoring: which startup is ahead?
In our wearable technology market deck, you will find everything you need to understand the market
SUMMARY
Photonic View Technology is ahead in non-invasive glucose monitoring today, but its lead is narrow and still rests on research hardware rather than a finished everyday product.
No company leads every part of the race. Photonic View has the strongest large calibration-free study, RSP Systems has the deepest repeated-use evidence, and Liom has the most credible wearable strategy.
Raman spectroscopy has quietly taken control of the scientific leaderboard. The top three companies all use it, which suggests the field is moving toward direct molecular measurement even though the optics remain difficult to shrink and manufacture.
The lowest headline error does not belong to the strongest study. HAGAR reported a 6.7% MARD, but Photonic View’s larger cohort, laboratory reference and calibration-free setup make its 14.6% result more convincing for a mass-market device.
Regulatory approval has not settled the technology question. Jingce Medical and Bobang Fangzhou already sell approved products in China, yet both remain supplementary tools with calibration or accuracy limitations that prevent them from replacing fingersticks or conventional CGMs.
Liom may still become the consumer winner. It has the most disclosed funding, the clearest plan for continuous wrist-worn monitoring and a 2028 launch target, but its published independent validation remains much smaller than the company’s product ambition.
Calibration is the dividing line between an impressive prototype and a scalable product. A device that needs repeated finger-prick setup can still be useful, but it gives up much of the convenience that makes non-invasive monitoring attractive in the first place.
The companies best prepared to manufacture today are not the ones with the strongest underlying science. Jingce and Bobang have regulated products and supply chains, while Photonic View, Liom and HAGAR are still trying to turn more promising sensing methods into reliable hardware.
The biggest competitive threat may come from outside the startup field. Apple, Samsung, Abbott and Dexcom have much larger engineering, regulatory and manufacturing resources, so proprietary human datasets and hard-to-reproduce hardware knowledge will matter more than patents alone.
Our conclusion is straightforward: Photonic View leads the science and the overall ranking, RSP is closest on evidence, and Liom has the best shot at building the product people actually want. None has yet proved calibration-free, multi-day continuous monitoring with the reliability of a conventional CGM.
This market map, featured in our wearable technology market deck, highlights top companies and startups in the wearable technology market
Non-invasive glucose monitoring: which startup is actually ahead?
Which non-invasive glucose-monitoring startups are really in the race?
The credible non-invasive glucose-monitoring field currently has nine startups with enough human data, regulatory progress or working hardware to deserve a serious comparison.
We include Photonic View Technology, RSP Systems, Liom, HAGAR, Jingce Medical, BOYDSense, DiaMonTech, Bobang Fangzhou and Afon Technology. They use methods ranging from Raman and infrared spectroscopy to radiofrequency waves, metabolic heat, microwaves and breath analysis, but all are trying to estimate glucose without puncturing the skin.
We use a strict definition. Biolinq, Nemaura and other microneedle companies are excluded because their sensors still enter the skin. Apple, Samsung and Huawei are also outside the startup comparison, and none currently sells an authorized watch that directly measures glucose without skin penetration. The FDA continues to warn consumers that it has not authorized any smartwatch or smart ring making that claim.
Occuity and Synex Medical remain worth watching, although neither has released enough comparable human glucose data to rank confidently. Know Labs is also left out because its ownership and strategy changed enough to make the former standalone glucose business difficult to assess. Lepu Medical has relevant products, but it is an established public medical-device company rather than a startup.
Funding is unusually hard to compare in this category. Some companies report grants, some disclose only one round, and several Chinese startups never publish a cumulative total. The table therefore shows the minimum amount we could verify publicly.
| Startup | What it is building | Where it stands now | Publicly disclosed funding |
|---|---|---|---|
| Photonic View Technology | Calibration-free Raman measurement using depth-selective micro-SORS | Large clinical study completed; first medical product in development | At least RMB 200 million, plus later undisclosed rounds |
| RSP Systems | Raman spectroscopy through the skin | Portable prototypes and repeated clinical studies | About $32 million in publicly tracked funding |
| Liom | Raman-based continuous glucose wearable | Clinical benchtop validation and active wearable development | CHF 63 million |
| HAGAR | Radiofrequency wrist sensor called GWave | Human feasibility data and a manufacturable sensor-chip concept | $25 million |
| Jingce Medical | Metabolic-heat device measured beneath the tongue | NMPA-approved and marketed in China | Not publicly disclosed |
| BOYDSense | Breath-based glucose estimation | Clinical study completed; portable breath prototype | €7 million disclosed capital increase |
| DiaMonTech | Mid-infrared photothermal glucose measurement | CE-certified desktop platform; portable D-Pocket still in development | More than $20 million, plus later undisclosed financing |
| Bobang Fangzhou | Metabolic-heat glucose meter measured at the finger | NMPA-approved and sold in China | At least RMB 50 million from one disclosed round; total unknown |
| Afon Technology | Microwave wrist wearable called Glucowear | Early real-world prototype testing | More than £2 million in public grant support |
Is any non-invasive glucose-monitoring startup clearly ahead today?
Photonic View is narrowly ahead overall today, with RSP Systems and Liom close enough that one strong trial or product milestone could change the order.
The three leaders are ahead for different reasons. Photonic View has the strongest large calibration-free study. RSP has spent longer testing repeated measurements and use outside the clinic. Liom has the clearest plan for turning spectroscopy into a wearable people might actually use every day.
Jingce Medical and Bobang Fangzhou lead on availability because they already have products on the Chinese market, while DiaMonTech has a longer regulatory history than most rivals. HAGAR sits just behind the top three because its radiofrequency technology may be easier to shrink, but its public clinical evidence remains limited.
So the field has a scientific top three, a few companies with genuine regulatory progress, and several higher-risk challengers. Photonic View leads, but not by much.
If you want more recent data on this point, please see our latest wearable technology market report.
As this chart shows, and as featured in our wearable technology market deck, search interest in smart rings has been increasing rapidly
Has any non-invasive glucose startup put a real product on sale?
Jingce Medical and Bobang Fangzhou have sold regulated non-invasive glucose devices in China, but no startup currently offers a broadly approved replacement for fingersticks or conventional CGMs.
Jingce’s combined glucometer received approval from China’s NMPA as a supplementary tool for adults with type 2 diabetes. The device places a metabolic-heat probe beneath the tongue and also contains an invasive measurement module. Public clinical disclosures report a 10.69% MARD, but a new user reportedly needs around ten invasive reference readings to build a personal calibration model.
Bobang’s earlier device measures metabolic and physiological signals at the fingertip. Its multicenter study reported a 27.02% MARD, and performance weakened during parts of the post-meal period. The approved product can provide extra readings without another finger prick, but patients cannot use the non-invasive value alone to replace standard testing or adjust treatment.
DiaMonTech’s desktop DMT Base obtained CE certification in 2019, yet broad commercialization never followed. The company has spent years developing the smaller D-Pocket instead. Regulatory clearance for a large clinical device did not automatically produce a practical consumer product.
We have not found any startup disclosing a large active-user base, recurring glucose-monitoring revenue or widespread physician adoption. The first commercial products are real, but none has become a primary glucose monitor.
Which startup has the strongest non-invasive glucose data?
Photonic View has the strongest overall clinical evidence, while RSP Systems has the best repeated calibrated result and HAGAR has the lowest headline error.
Photonic View’s Nature Metabolism study tested its depth-selective Raman system in a main cohort of 230 people. It reported a 14.6% MARD without personalized calibration, and 99.4% of estimates landed in the clinically acceptable zones of the consensus error grid. The study used venous plasma glucose as the reference.
The device still needed about eight minutes for each reading and was roughly desktop-computer sized. Accuracy also weakened in the low-glucose range. Photonic View has shown that its method can work across a relatively broad group of people, but not yet that it works quickly or continuously in a wearable.
RSP’s Scientific Reports study followed 50 adults with type 2 diabetes and produced 1,918 paired readings. Its portable Raman device reached a 12.8% MARD after ten reference measurements were used to personalize a pretrained model. RSP has also studied home use lasting up to 25 days.
RSP has shown more clearly that one person can use the system repeatedly. Photonic View has shown more clearly that one model can work across many people without a long personal setup. We give Photonic View the edge because a mass-market device cannot begin with hours of finger-prick calibration.
Liom’s published pilot involved 20 insulin-treated adults, with only five held out for validation. The reported MARD in that validation group was 14.5%. The result is promising, but five people cannot show how the algorithm will behave across a broad population.
HAGAR reported a 6.7% MARD across 75 participants, with every reading in Clarke error-grid zones A or B. Most participants contributed very few readings, and the reference was an average of consumer fingerstick values rather than a laboratory analyzer. The result deserves attention, but it still needs tougher testing.
| Startup | Human evidence | Reported performance | How much weight we give it |
|---|---|---|---|
| HAGAR | 75 participants, generally one or two readings each | 6.7% MARD; 100% in Clarke zones A and B | Striking result, but the comparator and limited repeated use make it less robust |
| RSP Systems | 50 participants and 1,918 paired readings | 12.8% MARD; 100% in consensus zones A and B | Strong repeated result, with a meaningful calibration burden |
| Liom | 20 participants, including five in the validation group | 14.5% MARD; 96.5% in DTS zones A and B | Promising and calibration-free, but based on a very small holdout sample |
| Photonic View | Main cohort of 230 participants | 14.6% MARD; 99.4% in consensus zones A and B | Strongest large calibration-free evidence, although still from a large, slow device |
| Jingce Medical | Multicenter clinical program disclosed around its approval | 10.69% MARD; 94.72% in Clarke zone A | Regulated result, but the personal invasive calibration limits comparability |
| DiaMonTech | Recent 36-person clinical evaluation | Below 20% MARD | Direct optical measurement, but accuracy remains behind the leading Raman systems |
| Bobang Fangzhou | 200 participants and 589 paired readings | 27.02% MARD; 93.9% in consensus zones A and B | Commercially real, but technically far behind the leading studies |
| BOYDSense | 130 adults, including a 30-person validation group | 98.7% in Parkes zones A and B | Good feasibility evidence, although no directly comparable MARD was published |
If you want more recent data on this point, please see our latest wearable technology market report.
This chart, included in our wearable technology market deck, illustrates yearly VC funding for wearable technology startups
Which startup is closest to a wearable non-invasive glucose monitor?
Liom is currently closest to a credible wearable, although its best clinical data still came from a benchtop system rather than the final watch-sized device.
Liom has built its strategy around continuous metabolic monitoring. The company says it has made a major miniaturization step, improved how much usable light the device captures and designed the platform around day-long battery use. It has also set a commercial launch target around 2028.
The hard part begins when the hardware leaves the bench. A wearable must handle sweat, movement, changing pressure, temperature shifts and rapid glucose swings. Liom’s study already showed less consistent performance during fast changes and in parts of the normal glucose range.
HAGAR may have the simpler hardware path. Its radiofrequency chip is designed for a wrist device and should fit more naturally into standard electronics manufacturing. It still needs a large dataset showing stable numerical readings across days and different users.
Afon recently tested Glucowear during normal activity and reported about 75% accuracy when separating normal from elevated glucose. One wearer and a classification task remain far from a medical CGM trial, but the update shows functioning wearable hardware outside the laboratory.
Photonic View is taking a slower route through a clinical device, while RSP’s current hardware and calibration process remain better suited to planned measurements. Liom leads the wearable race. HAGAR has the strongest alternative architecture.
Can any non-invasive glucose startup monitor continuously without calibration?
No startup has proved that a calibration-free non-invasive device can continuously track glucose with the multi-day reliability of a conventional CGM.
Personal calibration remains one of the field’s hardest problems. Skin thickness, hydration, temperature, tissue composition, placement and pressure can all change the signal. A model may work after learning one person’s body and then struggle with a new user, or with the same user under different conditions.
Photonic View’s published model worked without collecting each user’s glucose history first. Liom also reported calibration-free predictions, although its independent sample was small. HAGAR describes GWave as calibration-free, but its study did not follow people long enough to show whether drift or repositioning eventually forces a reset.
RSP starts with ten reference readings collected over a short period. That is an improvement over the weeks of calibration used in earlier work, but it still asks a new customer to prick a finger several times. Jingce uses a similar personal-model approach, while Bobang requires an invasive reference value during setup.
Continuous use adds another layer of difficulty. The sensor must stay stable through sleep, meals, exercise, sweat and motion while also catching low glucose and rapid changes.
RSP has the strongest repeated-use history, including home studies lasting up to 25 days, but the system still resembles repeated scanning more than an autonomous CGM. Liom is designing for continuous operation from the start, although it has not yet published multi-day traces from the miniaturized wearable.
HAGAR and Afon both describe continuous wrist monitoring, but their public human evidence remains too thin. Photonic View is still too slow in its current form, while BOYDSense, Jingce and Bobang are better understood as spot-measurement systems.
Photonic View leads on calibration-free evidence, RSP leads on repeated use and Liom leads on continuous product design. Nobody has combined all three.
This chart, included in our wearable technology market deck, shows why Whoop is leading in wearable technology
Which sensing technology looks strongest for non-invasive glucose monitoring?
Raman spectroscopy currently has the strongest human evidence, while radiofrequency sensing offers the cleaner route to a small, cheap wearable if HAGAR can validate it properly.
Photonic View, RSP and Liom all use Raman spectroscopy, which looks for molecular vibrations linked to glucose. These systems try to isolate a glucose-related optical signature rather than estimate glucose mainly from heat, circulation or broader tissue changes. The approach has produced the strongest peer-reviewed human studies in our comparison.
The weakness is hardware. Raman signals through skin are faint, so the device needs careful optics, enough laser power, sensitive detectors and algorithms that remove background noise. That explains why the best results still come from relatively large instruments and controlled positioning.
DiaMonTech uses mid-infrared photothermal detection, another direct optical approach. The company has credible clinical work and a long regulatory history, although its recent performance below 20% MARD still trails the top Raman systems.
HAGAR and Afon use radiofrequency or microwave signals. Their sensors could be smaller and easier to manufacture, but the measured signal can also change with hydration, blood flow, temperature and other tissue properties.
Jingce and Bobang estimate glucose from metabolic heat and other physiological inputs. Their approvals show that indirect models can become useful medical devices, but the calibration requirements and weaker published performance expose their limits. BOYDSense is even more indirect because breath compounds can shift with food, medication, oral health and wider metabolism.
If you want more recent data on this point, please see our latest wearable technology market report.
Which non-invasive glucose startup is closest to broader regulatory approval?
Jingce Medical and Bobang Fangzhou lead on approvals already obtained, while Photonic View looks best placed among the newer systems aiming for much better accuracy.
China’s NMPA approved Jingce’s combined glucometer as a supplementary device for adults with type 2 diabetes. Bobang also obtained Chinese approval for its fingertip metabolic-heat product. Both companies completed product development, clinical work, manufacturing documentation and quality controls.
Their indications remain narrow. The devices support existing glucose monitoring rather than replace it, and patients cannot rely on the non-invasive reading alone for treatment decisions.
DiaMonTech’s earlier CE certification proves that an optical non-invasive system can clear a European regulatory milestone. The absence of broad commercialization afterward suggests that the first product format was not practical enough.
Photonic View has the strongest package for the next serious submission: a large study, a laboratory-grade reference and no personal calibration. Its first target is a medical device rather than a watch, which reduces the initial burden around battery life, motion and continuous use. It still needs testing with the final hardware, better low-glucose performance and faster measurements.
RSP brings more real-life experience but must justify its calibration process. Liom needs a much larger trial with the wearable itself. HAGAR needs to reproduce its result against a laboratory reference over several days.
This chart, included in our wearable technology market deck, illustrates yearly funding for wearable technology startups
Which non-invasive glucose startup has found real customer demand?
No non-invasive glucose startup has yet proved strong, repeatable demand through transparent revenue, active-user or reorder data.
Jingce and Bobang have the clearest commercial foothold because their products are available in China. Public information shows hospital, pharmacy and community-health activity, but neither company discloses enough unit sales, repeat usage or physician retention to show that the devices are becoming routine diabetes tools.
DiaMonTech reached a regulated desktop product, yet years of work on the portable D-Pocket suggest that clinics and consumers did not turn the first format into a large market. RSP, Liom, Photonic View, HAGAR, BOYDSense and Afon remain largely pre-revenue in glucose monitoring.
A reusable optical or radiofrequency device could make each extra measurement almost free once the hardware is purchased. That advantage becomes much weaker when the customer must also buy test strips or CGM sensors because the non-invasive reading cannot guide treatment alone.
Jingce has disclosed pricing around RMB 3,900. Its invasive calibration and supplementary indication mean the device currently adds convenience rather than removing other monitoring costs.
The commercial winner will need to show regular use, repeat purchases or subscriptions, physician recommendations and a measurable reduction in other testing. None of the startups publishes that evidence today.
Which non-invasive glucose startup can manufacture at scale?
Jingce Medical and Bobang Fangzhou lead current manufacturing readiness, while Liom and Photonic View have the strongest plans for scaling a more capable next-generation product.
Jingce and Bobang have packaged devices, regulatory files, quality systems, assembly processes and distribution activity. They already know how to source components and support a regulated product, even though their technology is narrower than the leading optical prototypes.
Liom faces a harder manufacturing problem. Raman systems traditionally rely on costly lasers, detectors and tightly aligned optics. Its funding gives Liom a credible chance to solve those constraints, but production engineering can reveal problems that never appear in a laboratory unit.
Photonic View is trying to lower that risk through silicon photonics. The company is developing a chip-scale Raman spectrometer and plans to launch a larger medical system before moving toward smaller products.
HAGAR may eventually be easier to scale because a radiofrequency chip can use familiar semiconductor supply chains. The harder task will be making thousands of sensors behave consistently across different wrists.
RSP has built several portable prototype generations, while DiaMonTech’s long delay between desktop certification and portable launch shows how easily optical miniaturization can stretch into years of engineering.
Jingce and Bobang can manufacture today’s narrower products. Liom and Photonic View are trying to make the stronger technologies manufacturable.
This chart, included in our wearable technology market deck, compares the main business model options for wearable technology brands
Which non-invasive glucose startup has the hardest technology to copy?
Photonic View currently looks hardest to copy, while RSP Systems has the deepest practical experience and Liom has built the clearest wearable-engineering advantage.
Photonic View combines a depth-selective Raman system, a broad calibration-free dataset, chip-level work and more than 100 patent applications. A rival can understand the published physics, but recreating the probe, optical stack, processing pipeline and human training data would still take years.
RSP’s advantage comes from time and repetition. The company has worked on transdermal Raman sensing for well over a decade and across multiple prototype generations. That history gives it practical knowledge about drift, placement and user behavior.
Liom is solving a wider system problem across optics, electronics, battery life, thermal management, skin contact and signal processing. A competitor with a similar Raman method would still need to make every part work together.
HAGAR’s radiofrequency chip could become highly defensible if a large dataset proves that its model works reliably across many people. Regulatory approvals give Jingce and Bobang a head start in China, but a more accurate calibration-free product could weaken that advantage quickly.
The biggest threat comes from large incumbents. Apple, Samsung, Abbott and Dexcom have far larger engineering teams, supply chains and regulatory experience. A lasting startup lead will depend on proprietary human data and difficult hardware knowledge.
If you want more recent data on this point, please see our latest wearable technology market report.
Is the best-funded non-invasive glucose startup spending effectively?
Liom has the most disclosed funding, but Photonic View and RSP have so far produced more clinical evidence relative to the capital we can track publicly.
Liom’s CHF 63 million gives it more room than any rival to keep engineering, testing and preparing a launch. The company has published an early clinical study and recruited across photonics, medical devices and regulation, although the public validation sample remains small.
Photonic View disclosed a RMB 200 million angel round and later financing without publishing the amounts. Since then, it has produced the category’s strongest large calibration-free study and moved its Raman system toward a chip.
RSP has raised about $32 million according to current funding databases. That money has funded several prototype generations, repeated-use studies and a portable device tested outside the clinic.
HAGAR’s $25 million has produced a wrist-sensor architecture and a manufacturable chip concept, but the lack of a larger clinical follow-up now weighs more heavily.
DiaMonTech has raised more than $20 million and additional undisclosed financing. It published further clinical work and kept developing D-Pocket, but progress toward a portable launch has been slow.
Liom is best placed to finance a wearable launch. Photonic View has produced the strongest scientific result for the money we can see, while RSP has built a deep research base on a relatively modest disclosed total.
This chart, featured in our wearable technology market deck, illustrates how revenue is divided among customer segments in the wearable technology market
Which non-invasive glucose startup has the strongest momentum now?
Liom currently has the strongest momentum, with Photonic View close behind and Afon Technology finally showing fresh movement outside the leading group.
Liom added CHF 13 million to its Series A, bringing total funding to CHF 63 million, and paired that financing with a concrete miniaturization update. The company is now working toward a 2028 launch rather than an open-ended research program.
Photonic View is also moving its product forward. Its chip-scale Raman work addresses the size and cost of the original system, while its first planned product remains a medical device rather than a consumer watch.
Afon presented the freshest outsider update this year. Glucowear was worn during ordinary daily activity and achieved about 75% accuracy at distinguishing normal from elevated glucose. The experiment involved one wearer rather than a broad patient cohort, so it barely changes Afon’s evidence ranking, but it shows that the hardware has reached a real wrist-worn form.
RSP’s refreshed research database provides more detail on its newer prototypes, including a system designed to filter background light and collect a stronger signal. We treat this as clearer disclosure rather than a new clinical breakthrough.
HAGAR has lost relative momentum because a larger laboratory-reference study or multi-day wrist trial has not appeared publicly. BOYDSense’s 130-person breath study keeps it relevant, while DiaMonTech continues progressing without a clear launch milestone.
Which startups are actually ahead in non-invasive glucose monitoring?
Photonic View Technology is ahead overall, followed closely by RSP Systems and Liom, while the rest of the field remains at least one major result behind.
Photonic View takes first place because it has the best combination of clinical scale, calibration-free prediction and a believable route toward a usable medical product. Its lead will disappear if it cannot carry the study result into faster and smaller hardware.
RSP ranks second because it has tested non-invasive Raman sensing more deeply in repeated and home-use settings than any close rival. Its calibration burden and less aggressive wearable path keep it behind Photonic View.
Liom ranks third and has the best chance of becoming the consumer winner. It is the best-funded contender, has a genuine wearable strategy and is moving quickly. It still needs a much larger clinical trial using the miniaturized hardware itself.
HAGAR ranks fourth. Its wrist architecture could overturn the ranking, but the company first needs repeated real-world measurements against a laboratory reference.
Jingce ranks fifth because it has secured approval and placed a product on the market. Its invasive calibration, restricted indication and oral measurement process limit the broader opportunity.
DiaMonTech ranks sixth. The company has direct optical science, long regulatory experience and substantial funding, but the continuing wait for D-Pocket keeps it outside the leading group.
BOYDSense ranks seventh. Its clinical study is stronger than the typical breath-sensor experiment, yet the indirect biology and missing comparable MARD make the product difficult to judge.
Bobang ranks eighth. It deserves credit for early Chinese commercialization and real manufacturing, although its published accuracy remains well behind the leaders.
Afon ranks ninth because its public human evidence is still too early and narrow.
Photonic View leads the science, RSP leads repeated-use validation and Liom leads wearable productization. Today we would back Photonic View, but a large Liom wearable trial, a calibration-light RSP product or a rigorous HAGAR follow-up could change the ranking.
| Rank | Startup | Why it ranks here |
|---|---|---|
| 1 | Photonic View Technology | Best combination of large calibration-free evidence and a believable route from research hardware toward a medical product |
| 2 | RSP Systems | Deepest repeated-use experience, held back mainly by calibration and product form |
| 3 | Liom | Strongest wearable strategy, funding and current momentum, with clinical validation still too small |
| 4 | HAGAR | Attractive wrist architecture and impressive early evidence, but much weaker proof under demanding conditions |
| 5 | Jingce Medical | Approved and available in China, although it still needs invasive setup and has a restricted role |
| 6 | DiaMonTech | Long regulatory history and credible direct optical technology, without a successful portable rollout yet |
| 7 | BOYDSense | Largest serious breath-analysis study, but an indirect method with incomplete accuracy disclosure |
| 8 | Bobang Fangzhou | Real commercialization and manufacturing, with published performance far below the leading systems |
| 9 | Afon Technology | Fresh wearable progress, but human evidence remains too early and too narrow |
If you want more recent data on this point, please see our latest wearable technology market report.
This chart, included in our wearable technology market deck, shows how health monitoring wearable technology has evolved over time
OUR METHODOLOGY
This analysis compares the non-invasive glucose-monitoring startups with enough human data, regulatory progress or working hardware to support a serious assessment. We use a strict definition of non-invasive measurement and exclude microneedle sensors, established public medical-device companies and large technology groups.
We compare the companies across clinical evidence, calibration requirements, repeated and continuous use, wearable readiness, regulatory progress, commercial adoption, manufacturing, defensibility, capital efficiency and recent momentum. The final ranking gives the most weight to credible human validation and to whether the demonstrated technology can realistically become a product people could use outside a controlled study.
Accuracy figures are assessed in context rather than ranked at face value. We give more weight to larger validation groups, repeated measurements, laboratory-grade reference methods and tests using the intended product. Small samples, personal calibration, consumer fingerstick comparators and early prototypes still count, but they answer narrower questions.
We also separate scientific leadership from product leadership. A company can have the strongest calibration-free result without being closest to a wearable, while another can hold regulatory approval without offering a true replacement for fingersticks or conventional CGMs. Recent financing, miniaturization work and functioning hardware influence the ranking, but they do not override deeper clinical evidence.
Funding figures are treated as minimum publicly disclosed amounts because companies report equity rounds, grants, debt and strategic financing differently. Where adoption, revenue or cumulative funding was not disclosed, we did not fill the gap with estimates.
Key sources include the Nature Metabolism study of Photonic View Technology’s 230-participant calibration-free Raman system, the accompanying Nature Metabolism commentary on depth-selective Raman glucose measurement, the Scientific Reports study of RSP Systems’ calibrated Raman device, the FDA safety communication on unauthorized glucose-measuring smartwatches and smart rings, DiaMonTech’s disclosures on DMT Base CE certification and its 36-participant clinical evaluation, and Afon Technology’s report on its first real-world Glucowear test.
In our wearable technology market deck, we identify pain points entrepreneurs should prioritize
Related blog posts
- Which CGM platform has the edge?
